Search Results - "Capelletti, Marzia"

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors by Kosaka, Takayuki, Tanizaki, Junko, Paranal, Raymond M, Endoh, Hideki, Lydon, Christine, Capelletti, Marzia, Repellin, Claire E, Choi, Jihyun, Ogino, Atsuko, Calles, Antonio, Ercan, Dalia, Redig, Amanda J, Bahcall, Magda, Oxnard, Geoffrey R, Eck, Michael J, Jänne, Pasi A

“…Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these…”
Get full text

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors by Ercan, Dalia, Choi, Hwan Geun, Yun, Cai-Hong, Capelletti, Marzia, Xie, Ting, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A

“…Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclinical models and in lung…”
Get full text

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS by Ambrogio, Chiara, Köhler, Jens, Zhou, Zhi-Wei, Wang, Haiyun, Paranal, Raymond, Li, Jiaqi, Capelletti, Marzia, Caffarra, Cristina, Li, Shuai, Lv, Qi, Gondi, Sudershan, Hunter, John C., Lu, Jia, Chiarle, Roberto, Santamaría, David, Westover, Kenneth D., Jänne, Pasi A.

“…The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD),…”
Get full text

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant by Mouhieddine, Tarek H., Sperling, Adam S., Redd, Robert, Park, Jihye, Leventhal, Matthew, Gibson, Christopher J., Manier, Salomon, Nassar, Amin H., Capelletti, Marzia, Huynh, Daisy, Bustoros, Mark, Sklavenitis-Pistofidis, Romanos, Tahri, Sabrin, Hornburg, Kalvis, Dumke, Henry, Itani, Muhieddine M., Boehner, Cody J., Liu, Chia-Jen, AlDubayan, Saud H., Reardon, Brendan, Van Allen, Eliezer M., Keats, Jonathan J., Stewart, Chip, Mehr, Shaadi, Auclair, Daniel, Schlossman, Robert L., Munshi, Nikhil C., Anderson, Kenneth C., Steensma, David P., Laubach, Jacob P., Richardson, Paul G., Ritz, Jerome, Ebert, Benjamin L., Soiffer, Robert J., Trippa, Lorenzo, Getz, Gad, Neuberg, Donna S., Ghobrial, Irene M.

“…Multiple myeloma (MM) is a plasma-cell neoplasm that is treated with high-dose chemotherapy, autologous stem cell transplant (ASCT) and long-term…”
Get full text

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer by MUSOLINO, Antonino, NALDI, Nadia, NERI, Tauro Maria, ARDIZZONI, Andrea, BORTESI, Beatrice, PEZZUOLO, Debora, CAPELLETTI, Marzia, MISSALE, Gabriele, LACCABUE, Diletta, ZERBINI, Alessandro, CAMISA, Roberta, BISAGNI, Giancarlo

“…The anti-HER-2/neu monoclonal antibody trastuzumab has been shown to engage both activatory (fragment C receptor [Fc gamma R]IIIa; Fc gamma RIIa) and…”
Get full text

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer by Tricker, Erin M, Xu, Chunxiao, Uddin, Sharmeen, Capelletti, Marzia, Ercan, Dalia, Ogino, Atsuko, Pratilas, Christine A, Rosen, Neal, Gray, Nathanael S, Wong, Kwok-Kin, Jänne, Pasi A

“…Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR-activating and EGFR inhibitor-resistant T790M mutations more…”
Get more information

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors by SASAKI, Takaaki, KOIVUNEN, Jussi, CAPELLETTI, Marzia, SHIMAMURA, Takeshi, ERCAN, Dalia, STUMPFOVA, Magda, YUN XIAO, WEREMOWICZ, Stanislawa, BUTANEY, Mohit, HEON, Stephanie, WILNER, Keith, CHRISTENSEN, James G, OGINO, Atsuko, ECK, Michel J, WONG, Kwok-Kin, LINDEMAN, Neal, GRAY, Nathanael S, RODIG, Scott J, JÄNNE, Pasi A, YANAGITA, Masahiko, NIKIFOROW, Sarah, ZHENG, Wei, LATHAN, Christopher, PAUL MARCOUX, J, JINYAN DU, OKUDA, Katsuhiro

“…Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and in cancer patients…”
Get full text

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer by Chong, Curtis R, Bahcall, Magda, Capelletti, Marzia, Kosaka, Takayuki, Ercan, Dalia, Sim, Taebo, Sholl, Lynette M, Nishino, Mizuki, Johnson, Bruce E, Gray, Nathanael S, Jänne, Pasi A

“…Efforts to discover drugs that overcome resistance to targeted therapies in patients with rare oncogenic alterations, such as NTRK1 and ROS1 rearrangements,…”
Get full text

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC by Turke, Alexa B., Zejnullahu, Kreshnik, Wu, Yi-Long, Song, Youngchul, Dias-Santagata, Dora, Lifshits, Eugene, Toschi, Luca, Rogers, Andrew, Mok, Tony, Sequist, Lecia, Lindeman, Neal I., Murphy, Carly, Akhavanfard, Sara, Yeap, Beow Y., Xiao, Yun, Capelletti, Marzia, Iafrate, A. John, Lee, Charles, Christensen, James G., Engelman, Jeffrey A., Jänne, Pasi A.

“…MET amplification activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers and causes resistance to EGFR kinase inhibitors. We demonstrate that MET…”
Get full text

Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy by SHEPHERD, Frances A, DOMERG, Caroline, BOURREDJEM, abderrahmane, LE TEUFF, Gwénaël, PIRKER, Robert, FILIPITS, Martin, ROSELL, Rafael, KRATZKE, Robert, BANDARCHI, Bizhan, XIAOLI MA, CAPELLETTI, Marzia, SORIA, Jean-Charles, HAINAUT, Pierre, TSAO, Ming-Sound, JÄNNE, Pasi A, PIGNON, Jean-Pierre, GRAZIANO, Stephen, DOUILLARD, Jean-Yves, BRAMBILLA, Elizabeth, LE CHEVALIER, Thierry, SEYMOUR, Lesley

“…We undertook this analysis of KRAS mutation in four trials of adjuvant chemotherapy (ACT) versus observation (OBS) to clarify the prognostic/predictive roles…”
Get full text

Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway by CORTOT, Alexis B, REPELLIN, Claire E, SHIMAMURA, Takeshi, CAPELLETTI, Marzia, ZEJNULLAHU, Kreshnik, ERCAN, Dalia, CHRISTENSEN, James G, WONG, Kwok-Kin, GRAY, Nathanael S, JÄNNE, Pasi A

“…The clinical efficacy of EGF receptor (EGFR) kinase inhibitors gefitinib and erlotinib is limited by the development of drug resistance. The most common…”
Get full text

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance by Johnson, Neil, Johnson, Shawn F., Yao, Wei, Li, Yu-Chen, Choi, Young-Eun, Bernhardy, Andrea J., Wang, Yifan, Capelletti, Marzia, Sarosiek, Kristopher A., Moreau, Lisa A., Chowdhury, Dipanjan, Wickramanayake, Anneka, Harrell, Maria I., Liu, Joyce F., D'Andrea, Alan D., Miron, Alexander, Swisher, Elizabeth M., Shapiro, Geoffrey I.

“…Breast Cancer Type 1 Susceptibility Protein (BRCA1)-deficient cells have compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP)…”
Get full text

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors by Tan, Li, Wang, Jun, Tanizaki, Junko, Huang, Zhifeng, Aref, Amir R, Rusan, Maria, Zhu, Su-Jie, Zhang, Yiyun, Ercan, Dalia, Liao, Rachel G, Capelletti, Marzia, Zhou, Wenjun, Hur, Wooyoung, Kim, NamDoo, Sim, Taebo, Gaudet, Suzanne, Barbie, David A, Yeh, Jing-Ruey Joanna, Yun, Cai-Hong, Hammerman, Peter S, Mohammadi, Moosa, Jänne, Pasi A, Gray, Nathanael S

“…The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation…”
Get full text

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition by Soucheray, Margaret, Capelletti, Marzia, Pulido, Inés, Kuang, Yanan, Paweletz, Cloud P, Becker, Jeffrey H, Kikuchi, Eiki, Xu, Chunxiao, Patel, Tarun B, Al-Shahrour, Fatima, Carretero, Julián, Wong, Kwok-Kin, Jänne, Pasi A, Shapiro, Geoffrey I, Shimamura, Takeshi

“…Non-small cell lung cancers (NSCLC) that have developed resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI), including gefitinib and erlotinib,…”
Get full text

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers by Sasaki, Takaaki, Okuda, Katsuhiro, Zheng, Wei, Butrynski, James, Capelletti, Marzia, Wang, Liping, Gray, Nathanael S, Wilner, Keith, Christensen, James G, Demetri, George, Shapiro, Geoffrey I, Rodig, Scott J, Eck, Michael J, Jänne, Pasi A

“…The ALK kinase inhibitor crizotinib (PF-02341066) is clinically effective in patients with ALK-translocated cancers, but its efficacy will ultimately be…”
Get full text

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial by JÄNNE, Pasi A, XIAOFEI WANG, VOKES, Everett E, MILLER, Vincent A, SOCINSKI, Mark A, CRAWFORD, Jeffrey, STINCHCOMBE, Thomas E, LIN GU, CAPELLETTI, Marzia, EDELMAN, Martin J, VILLALONA-CALERO, Miguel A, KRATZKE, Robert

“…Erlotinib is clinically effective in patients with non-small-cell lung cancer (NSCLC) who have adenocarcinoma, are never or limited former smokers, or have…”
Get full text

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer by Redig, Amanda J, Capelletti, Marzia, Dahlberg, Suzanne E, Sholl, Lynette M, Mach, Stacy, Fontes, Caitlin, Shi, Yunling, Chalasani, Poornima, Jänne, Pasi A

“…NF1 is a tumor suppressor that negatively regulates Ras signaling. NF1 mutations occur in lung cancer, but their clinical significance is unknown. We evaluated…”
Get full text

A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer by Wilson, Frederick H., Johannessen, Cory M., Piccioni, Federica, Tamayo, Pablo, Kim, Jong Wook, Van Allen, Eliezer M., Corsello, Steven M., Capelletti, Marzia, Calles, Antonio, Butaney, Mohit, Sharifnia, Tanaz, Gabriel, Stacey B., Mesirov, Jill P., Hahn, William C., Engelman, Jeffrey A., Meyerson, Matthew, Root, David E., Jänne, Pasi A., Garraway, Levi A.

“…We conducted a large-scale functional genetic study to characterize mechanisms of resistance to ALK inhibition in ALK-dependent lung cancer cells. We identify…”
Get full text

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma by Mishima, Yuji, Paiva, Bruno, Shi, Jiantao, Park, Jihye, Manier, Salomon, Takagi, Satoshi, Massoud, Mira, Perilla-Glen, Adriana, Aljawai, Yosra, Huynh, Daisy, Roccaro, Aldo M., Sacco, Antonio, Capelletti, Marzia, Detappe, Alexandre, Alignani, Diego, Anderson, Kenneth C., Munshi, Nikhil C., Prosper, Felipe, Lohr, Jens G., Ha, Gavin, Freeman, Samuel S., Van Allen, Eliezer M., Adalsteinsson, Viktor A., Michor, Franziska, San Miguel, Jesus F., Ghobrial, Irene M.

“…The development of sensitive and non-invasive “liquid biopsies” presents new opportunities for longitudinal monitoring of tumor dissemination and clonal…”
Get full text

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors by Ercan, Dalia, Xu, Chunxiao, Yanagita, Masahiko, Monast, Calixte S, Pratilas, Christine A, Montero, Joan, Butaney, Mohit, Shimamura, Takeshi, Sholl, Lynette, Ivanova, Elena V, Tadi, Madhavi, Rogers, Andrew, Repellin, Claire, Capelletti, Marzia, Maertens, Ophélia, Goetz, Eva M, Letai, Anthony, Garraway, Levi A, Lazzara, Matthew J, Rosen, Neal, Gray, Nathanael S, Wong, Kwok-Kin, Jänne, Pasi A

“…The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR…”
Get more information